Filing Details
- Accession Number:
- 0000950170-24-015358
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-14 17:26:31
- Reporting Period:
- 2024-02-12
- Accepted Time:
- 2024-02-14 17:26:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1994702 | Kyverna Therapeutics Inc. | KYTX | () | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1703031 | Bain Capital Life Sciences Investors, Llc | 200 Clarendon Street Boston MA 02116 | No | No | No | No | |
| 1875273 | Bain Capital Life Sciences Fund Iii, L.p. | 200 Clarendon Street Boston MA 02116 | No | No | No | No | |
| 1950105 | Bain Capital Life Sciences Opportunities Iii, Lp | 200 Clarendon Street Boston MA 02116 | No | No | No | No | |
| 1952106 | Bain Capital Life Sciences Iii General Partner, Llc | 200 Clarendon Street Boston MA 02116 | No | No | No | No | |
| 1964467 | Bain Capital Life Sciences Opportunities Iii Gp, Llc | 200 Clarendon Street Boston MA 02116 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-12 | 2,713,868 | $0.00 | 2,713,868 | No | 4 | C | Indirect | See footnotes |
| Common Stock | Acquisiton | 2024-02-12 | 450,000 | $22.00 | 3,163,868 | No | 4 | P | Indirect | See footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See footnotes |
| No | 4 | P | Indirect | See footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2024-02-12 | 12,351,087 | $0.00 | 2,713,868 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of the Issuer's Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a ratio of one-for-4.5511 immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date.
- Represents 12,351,087 shares of the Issuer's Series B Convertible Preferred Stock held directly by Bain Capital Life Sciences Opportunities III, LP ("BCLS Fund III Opportunities").
- Represents 450,000 shares of the Issuer's Common Stock purchased by BCLS Fund III Opportunities in the Issuer's initial public offering.
- Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences III General Partner, LLC ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS Fund III"), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC ("BCLS Fund III Opportunities GP"), which is the general partner of BCLS Fund III Opportunities. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Opportunities GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Opportunities. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Opportunities GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Billionaire Hedge Funds
